Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanz Zeroes In On Innovative Assets And M&A

Business Has Increased In Value To Around €670m

Executive Summary

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

You may also be interested in...



Burden Departs Advanz As Intercept Deal Completes

As Advanz completes its deal to acquire Intercept’s ex-US business, the company has confirmed a management change that has seen chief commercial officer Paul Burden leave the company, with the appointment of two new regional CCOs.

Generics Bulletin Podcast – GenBioPro v. West Virginia: The Future Of Mifepristone In America, With Professor Greer Donley

Generics Bulletin spoke to University of Pittsburgh School of Law professor Greer Donley, a specialist in reproductive law, about generic mifepristone manufacturer GenBioPro’s lawsuit challenging West Virginia’s state-level restrictions on medical abortion access and its potential wider relevance for the industry.

Instead Of VC, Try Philanthropy: Inside Medical Research Charity LifeArc

In Vivo reporter Chloe Kent caught up with Life Arc CEO Melanie Lee to discuss the power of philanthropy in early-stage biopharma funding.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel